Markers of inflammation are predictive of cardiovascular events but their association with atherosclerotic burden remains poorly defined. We hypothesized that markers of inflammation, including C-reactive protein (CRP), white blood cell (WBC) count, and lipoproteinassociated phospholipase A2 (Lp-PLA2), would be associated with the ankleÀbrachial index (ABI), a marker of atherosclerotic burden. Subjects were 247 patients referred for lower extremity arterial evaluation to the non-invasive vascular laboratory excluding those with active infection or lower extremity revascularization within the previous year. ABI was measured at two sites in both legs and the lowest of four measurements was used in the analyses. CRP was measured by a high-sensitivity immunoturbidimetric assay and Lp-PLA2 was measured by ELISA. The mean patient age was 68AE11 years, and 54% were men. Mean ABI was 0.84 AE 0.31 and 49% had an ABI < 0.9. Age, hypertension, fasting plasma glucose, and 'ever' smoking were independently associated with the ABI. Spearman correlation coefficients of inflammatory markers with the ABI were: CRP (r ¼ À0.15, p ¼ 0.02), WBC count (r ¼ À0.27, p ¼ 0.001), and Lp-PLA2 (r ¼ À0.09, p ¼ 0.21). In a multiple regression model that included conventional risk factors and statin use, CRP and WBC count were no longer significantly associated with ABI, whereas Lp-PLA2 was a borderline-significant predictor of lower ABI (p ¼ 0.05). These data indicate that CRP and WBC count are not independently associated with ABI, a marker of atherosclerotic burden in subjects referred for non-invasive lower extremity arterial evaluation. The association of Lp-PLA2 with ABI merits further study.
Introduction
Atherosclerosis is now considered a chronic inflammatory disorder that affects the arterial bed in a diffuse but nonuniform manner. 1 The ankleÀbrachial index (ABI) is a simple non-invasive measure of lower extremity atherosclerosis. The presence and severity of atherosclerosis in the lower extremities is correlated with disease in other arterial beds. A decreased ABI is indicative of generalized atherosclerosis, and has been shown to be predictive of cardiovascular events. 2À4 Several studies have demonstrated circulating levels of markers of inflammation to be predictive of cardiovascular events in asymptomatic individuals. 5À7 Whether markers of inflammation are associated with the ABI is unclear. This is an important area of investigation since an association of markers of inflammation with atherosclerotic burden would suggest that they mediate an increase in cardiovascular risk by promoting atherogenesis. On the other hand, lack of an association would imply that inflammatory markers may reflect atherosclerotic plaque activity rather than plaque burden.
Previously, in a large cross-sectional family-based study, Folsom and colleagues 8 noted a weak inverse correlation between C-reactive protein (CRP) and ABI in men, independent of other risk factors. However, no association was noted in women. We investigated whether markers of inflammation, including CRP, white blood cell (WBC) count, and lipoprotein-associated phospholipase A2 (Lp-PLA2), are associated with the ABI in subjects undergoing non-invasive lower extremity arterial evaluation, after adjusting for conventional risk factors for atherosclerosis. CRP and WBC count are acute-phase reactants and wellestablished markers of systemic inflammation, whereas Lp-PLA2 has been recently proposed as a marker of vascular inflammation. 9À11
Methods
The study protocol was approved by the Institutional Review Board of Mayo Clinic. Subjects included 247 patients referred for lower extremity arterial evaluation to the non-invasive vascular laboratory who did not meet any of the exclusion criteria. Subjects were excluded if they had an ongoing febrile illness, history of a connective tissue disorder, non-atherosclerotic arterial disease, history of lower extremity bypass or percutaneous angioplasty in the preceding year.
Patients' medical records were reviewed for referral to the non-invasive vascular laboratory, symptoms of claudication, rest pain, or ischemic ulceration, and for presence of any infectious inflammatory illness. Leg symptoms were categorized as intermittent claudication and atypical leg pain (leg symptoms that were not consistent with intermittent claudication).
Information about the use of medications that could affect the inflammatory response was obtained from the medical record. The medications included 'statins', oral estrogen, angiotensin-converting enzyme inhibitors (ACEI), and aspirin. Diabetes was considered present if a patient was being treated with insulin or oral agents or had a fasting glucose level of !126 mg=dl (!7 mmol=l). Hypertension was defined as a blood pressure !140= 90 mmHg or current use of antihypertensive drugs.
Smoking status was classified as current, 'ever' or 'never'. 'Ever' smoking was defined as a history of current or past smoking. A history of myocardial infarction or nonhemorrhagic stroke was ascertained by reviewing the medical record.
AnkleÀbrachial indices were measured in the noninvasive vascular laboratory after 10 min of rest in the supine position at two sites (posterior tibial artery and the dorsalis pedis artery) in each leg. Appropriately sized blood pressure cuffs were placed over each brachial artery and above each malleolus, and systolic blood pressures were measured using a hand-held 5-MHz Doppler probe (Meda Sonics, Fremont, CA, USA). The higher of the two systolic brachial arterial pressures was used to calculate the ABI. The lowest of the four ankleÀbrachial indices was used in the analyses. Inferences were unchanged if the average or the higher ABI was used. Subjects with an ABI of >1.3 may have non-compressible vessels and were therefore excluded from analyses.
Blood tests were performed on a sample obtained by venipuncture after an overnight fast. Serum cholesterol and high-density lipoprotein (HDL) cholesterol were measured by standard enzymatic methods. Plasma glucose was measured by the glucose oxidase method. WBC count was measured with the use of a commercially available automated system (COULTER 1 GEN. S TM , Coulter Corporation, Miami, FL, USA).
Sample aliquots for CRP and Lp-PLA2 analysis were obtained at the clinic visit, during which lower extremity arterial studies were performed. Samples were stored at À70 C until analysis. CRP was determined using a highly sensitive latex particle enhanced immunoturbidometric assay on a Hitachi 912 automated analyzer as previously described. 12 Inter-assay precision for the assay was evaluated at four levels: 0.33, 1.05, 9.07, and 23.8 mg=dl, with coefficients of variation of 14%, 3.2%, 3.4%, and 3.6%, respectively (n ¼ 20). The lower limit of the working range of the assay was 0.015 mg=dl. 12 Lp-PLA2 was measured by an enzyme-linked immunosorbent assay (ELISA) using the PLAC TM test (diaDexus, Inc., South San Francisco, CA, USA). The antibodies used in this method have been previously described 9 and the method was validated in the Mayo Biochemical Genetics Laboratory. Serial dilution of three patient serum samples demonstrated that the method was linear from 30 to at least 1100 ng=ml (mean regression equation:
Inter-assay coefficients of variation were 21%, 8.6% and 12% at 102, 255, and 290 ng=ml, respectively. In 112 healthy volunteers (56 men, 56 women), Lp-PLA2 values ranged from 90 to 550 ng=ml (mean ¼ 246 ng=ml).
Statistical analysis
All descriptive data were expressed as mean AE standard deviation and categorical data as percentages. CRP and triglycerides were log-transformed to reduce skewness. The correlation of markers of inflammation with conventional risk factors and the ABI was assessed by Spearman's rank test. With a sample size of 247 patients, the smallest correlation (simple or partial) detectable with 80% power was 0.18, while an observed correlation of 0.13 or more would be significant. Differences in the mean levels of the inflammatory markers in various subgroups were assessed by the t-test or the Wilcoxon rank sum test.
The association of the conventional risk factors with ABI as a continuous variable was assessed by simple and multiple linear regression. Independent association with the ABI for each marker of inflammation was assessed in a multiple regression model that included the univariable predictors of ABI. Since statins have been shown to modify markers of inflammation, statin use was added to the multiple regression model. In separate analyses, we also included ACE inhibitor use and aspirin therapy to the multiple regression model.
Statistical significance was defined as p < 0.05. Analyses were performed using SAS v 8.2 (SAS Institute, Cary, NC, USA).
Results
Sample characteristics are shown in Table 1 . Reasons for referral for non-invasive lower extremity evaluation included 'rest pain' (3%), 'screening' (13%), 'leg pain', (20%), and 'claudication' (64%). After reviewing the medical records, symptoms consistent with claudication appeared to be present in 52% of patients. A history of myocardial infarction or ischemic cerebrovascular accident was present in 12% of the patients.
As expected, increasing age, smoking history, hypertension, and higher fasting blood glucose were predictive of a lower ABI. However, we did not find gender or any of the plasma lipid variables to be associated with the ABI.
CRP was significantly related to the WBC count but no significant correlation was noted between CRP and Lp-PLA2, or between WBC count and Lp-PLA2 (Table 2) . CRP was significantly correlated with systolic blood pressure, Lp-PLA2 with total cholesterol and (inversely) with HDL cholesterol, and WBC count (inversely) with HDL cholesterol. Of the three markers of inflammation, WBC count and CRP, but not Lp-PLA2 correlated with the ABI.
Smoking history, gender, and medications affected the markers of inflammation in a differential manner (Table  3 ). CRP and WBC count, but not Lp-PLA2, were significantly higher in 'ever' smokers than in 'never' smokers. CRP levels were higher in women than in men. In women, estrogen use was associated with higher CRP but lower Lp-PLA2 levels. Patients on statins or aspirin had significantly lower levels of Lp-PLA2 than those not on statins or aspirin. CRP levels tended to be lower in patients on statins than those not on statins, but the difference was not statistically significant.
Univariate associates of the ABI included age, hypertension, smoking, fasting plasma glucose, WBC count, and CRP (Table 4 ). Lp-PLA2 was not associated with the ABI in univariate analyses. In a multiple regression model that included the univariate associates and statin-use, age, hypertension, fasting plasma glucose, and 'ever' smoking remained independent predictors of ABI (Table 5 ). In this model, Lp-PLA2 was associated with the ABI in a borderline-significant manner, whereas WBC count and log CRP were no longer associated with the ABI (Table 5 ). For both WBC count and CRP, the main confounding factor was 'ever' smoking. Inclusion of ACEI use and estrogen therapy into the multiple regression model did not change the results (analyses not shown).
Discussion
Although we found an association of CRP with the ABI, this did not persist after adjusting for smoking status, suggesting that the association was confounded by smok-ing status. Our findings are similar to those of McDermott and colleagues who recently reported that in 501 subjects identified from non-invasive vascular laboratories and general medicine practice, CRP was related to the ABI, but not after adjusting for conventional risk factors. 13 We found CRP levels to be significantly higher in women than in men, in women on estrogen than in women not on estrogen, and in current and 'ever' smokers than in 'never' smokers. These observations provide an 'internal validation' of the CRP assay used in this study.
In the Physician's Health Study, baseline levels of CRP were predictive of not only cardiovascular events but also of the risk of developing symptomatic peripheral arterial disease in men, even after adjusting for conventional risk factors. 5, 14 It is possible that at earlier stages of atherogenesis, CRP may be related to atherosclerotic burden and perhaps rate of progression of atherosclerosis. 15 However, among symptomatic patients with peripheral arterial disease, CRP levels have not been found to be significantly different in varying grades of claudication severity, implying that CRP was not related to the severity of obstructive peripheral arterial disease. 16 Although Langlois and colleagues 17 noted significantly higher levels of CRP in subjects with peripheral arterial disease compared with a matched group of hypertensives without peripheral arterial disease, no adjustment was reported for smoking and other cardiovascular risk factors.
The WBC count has previously been shown to be related to cardiovascular events. In a meta analyses of seven studies that included 5337 cases of coronary heart disease, WBC count in the upper tertile was associated with a risk ratio of 1.4 (95%; confidence interval: 1.3, 1.5) for cardiovascular events, compared with a WBC count in the bottom tertile. 6 In the present study, WBC count was significantly associated with the ABI in univariate analysis, but as with CRP, the association did not remain significant after adjusting for smoking status. Of note, the association of WBC count with the ABI appeared to be stronger than that of CRP in univariate analyses and less attenuated by adjusting for conventional risk factors in multivariate analyses.
The expression of Lp-PLA2 appears to be regulated by inflammatory cytokines. 18 However, we did not find Lp-PLA2 to be correlated with WBC count and CRP. Packard and colleagues 10 also did not find a correlation between WBC count and CRP with Lp-PLA2 in dyslipidemic middle-aged men participating in the West of Scotland Prevention (WOSCOP) study. We also noted that plasma levels of Lp-PLA2 were not significantly different in 'ever' smokers compared with 'never' smokers. In the present study, therefore, Lp-PLA2 levels do not appear to reflect systemic inflammation. The borderline association of Lp-PLA2 with ABI in a multivariate model appears to be independent of systemic inflammation. The possibility exists that Lp-PLA2 may be a marker of vascular rather than systemic inflammation. 11 Lp-PLA2 has been implicated in LDL oxidation and generation of lysophosphatidylcholine, a molecule with several pro-atherogenic properties. 9, 19, 20 Caslake and colleagues noted Lp-PLA2 levels to be higher in patients with angiographic coronary artery disease compared with control subjects. 9 Lp-PLA2 was independently predictive of the risk of myocardial infarction in the WOSCOP study. 10 In a prospective, nested, caseÀcontrol study of apparently healthy middleaged women, elevated levels of Lp-PLA2 were associated with an increased risk of future cardiovascular events but not after adjusting for other risk factors. 21 Further studies are needed to assess the role of Lp-PLA2 as a marker of atherosclerotic burden, and as a predictor of cardiovascular events.
The present study is observational and cross-sectional in nature and hence any associations cannot be presumed to be causal. The referral nature of the study population leads to an inherent referral bias. We cannot exclude the possibility that in younger subjects the association of markers of inflammation with atherosclerotic burden may be different. In addition, we assessed subclinical atherosclerosis in the peripheral arterial bed and not in other arterial beds. However, the ABI is considered a surrogate for generalized atherosclerosis and patients with peripheral arterial disease typically have widespread atherosclerotic disease. 2, 3 
Conclusion
In a sample of individuals referred for non-invasive lower extremity arterial evaluation, markers of systemic inflammation (CRP and WBC count) were not indepen-dently associated with the ABI, a marker of generalized atherosclerosis. Lp-PLA2 appeared to be weakly associated with the ABI, independent of the conventional risk factors. Further studies are needed to fully characterize the relationship of Lp-PLA2 with atherosclerotic burden.
Elevated CRP as well as a low ABI have been associated with increased risk of cardiovascular events, 6, 22 suggesting that these measures predict risk through divergent pathways. In subjects with symptomatic peripheral arterial disease undergoing revascularization, preprocedural measurements of CRP are predictive of subsequent myocardial infarction. 16 Recently, CRP combined with coronary artery calcification score has been demonstrated to have a greater predictive value for cardiovascular events than either measure alone. 23 Combined use of a marker of inflammation and ABI may therefore have a greater predictive value for cardiovascular events than either measure alone. This hypothesis warrants testing in a prospective study.
